LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. The company is headquartered in Princeton, New Jersey and currently employs 163 full-time employees. The company went IPO on 2021-10-28. The firm is also pursuing the sale of its remaining pipeline assets.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for LIANY. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: LIANY is a Sell candidate.
LIANY stock price ended at $0.09 on 星期一, after rising 0.00%
On the latest trading day Jan 26, 2026, the stock price of LIANY rose by 0.00%, climbing from $0.09 to $0.09. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.09 and a high of $0.09. Notably, trading volume dropped by 292 shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 3.8K shares were traded, equating to a market value of approximately $9.7M.
投資組合